|Dr. Geraldine A. Henwood||Pres, CEO & Director||819.43k||N/A||1952|
|Mr. Ryan D. Lake||Chief Financial Officer||414.29k||N/A||1977|
|Mr. Randall J. Mack||Sr. VP of Devel. & Corp. Sec.||N/A||N/A||1965|
|Ms. Diane Myers||Sr. VP of Regulatory Affairs & Quality Assurance||N/A||N/A||1964|
|Dr. Stewart McCallum||Chief Medical Officer||N/A||N/A||1966|
Recro Pharma, Inc. operates as a specialty pharmaceutical company. It operates through two divisions, an Acute Care, and Contract Development and Manufacturing (CDMO). The Acute Care division primarily focuses on developing products for the hospital and other acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has completed two pivotal Phase III clinical efficacy trials, a double-blind placebo-controlled Phase III safety trial, and four Phase II clinical efficacy trials, as well as other safety studies. Its pipeline also includes other early-stage product candidates, including two novel neuromuscular blocking agents and a related proprietary chemical reversal agent, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine or Dex an alpha-2 adrenergic agonist. The CDMO division leverages its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies and other manufacturing services for commercial and development-stage partners who commercialize or plan to commercialize these products. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Recro Pharma, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 8.